Potential solutions for manufacture of CAR T cells in cancer immunotherapy.
Where this comes from
- Record sourced from PubMed, PMID 36064867.
- Also identified by DOI 10.1038/s41467-022-32866-0 and PMC identifier 9445013.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
CAR T cell therapy is an effective cancer treatment, but biological and manufacturing hurdles hamper its broad breakthrough. Although the first step towards automated manufacture of CAR cells has been taken, new technologies are needed to enable the treatment of large patient groups.
Medical subject headings
- Neoplasms
- Receptors, Chimeric Antigen